Paolo Capogrosso1, Alessandro Larcher2, Daniel D Sjoberg3, Emily A Vertosick3, Francesco Cianflone2, Paolo Dell'Oglio2, Cristina Carenzi4, Andrea Salonia2, Andrew J Vickers3, Francesco Montorsi2, Roberto Bertini2, Umberto Capitanio2. 1. Università Vita-Salute San Raffaele, Milan, Italy; Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: paolo.capogrosso@gmail.com. 2. Università Vita-Salute San Raffaele, Milan, Italy; Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. 3. Memorial Sloan Kettering Cancer Center, New York, New York. 4. Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Abstract
PURPOSE: We assessed the accuracy of the UISS (UCLA Integrated Staging System) to predict the postoperative recurrence of renal cell carcinoma. We also evaluated whether including patient age and tumor histology would improve clinical decision making. MATERIALS AND METHODS: We analyzed the records of 1,630 patients treated with nephrectomy at a single academic center. The accuracy of the UISS model to predict early (12 months or less) and late (more than 60 months) recurrence after surgery was compared with a new model including patient age and disease histology. RESULTS: The new model and the UISS model showed high accuracy to predict early recurrence after surgery (AUC 0.84, 95% CI 0.81-0.88 and 0.83, 95% CI 0.80-0.87, respectively). In patients diagnosed with low risk tumor types (eg papillary type 1 and chromophobe lesions) the average risk of early recurrence significantly decreased in each UISS risk category when tumor histology was added to the predictive model (low risk 1.6% vs 0.6%, intermediate risk 5.5% vs 1.9% and high risk 45% vs 22%). Kaplan-Meier analysis showed no difference in the risk of late recurrence among the UISS risk categories. CONCLUSIONS: The UISS model should be applied to tailor the early followup protocol after nephrectomy. Patients with low risk histology deserve less stringent followup regardless of the UISS risk category. Our results do not support a risk stratification model to design a surveillance protocol after 5 years postoperatively.
PURPOSE: We assessed the accuracy of the UISS (UCLA Integrated Staging System) to predict the postoperative recurrence of renal cell carcinoma. We also evaluated whether including patient age and tumor histology would improve clinical decision making. MATERIALS AND METHODS: We analyzed the records of 1,630 patients treated with nephrectomy at a single academic center. The accuracy of the UISS model to predict early (12 months or less) and late (more than 60 months) recurrence after surgery was compared with a new model including patient age and disease histology. RESULTS: The new model and the UISS model showed high accuracy to predict early recurrence after surgery (AUC 0.84, 95% CI 0.81-0.88 and 0.83, 95% CI 0.80-0.87, respectively). In patients diagnosed with low risk tumor types (eg papillary type 1 and chromophobe lesions) the average risk of early recurrence significantly decreased in each UISS risk category when tumor histology was added to the predictive model (low risk 1.6% vs 0.6%, intermediate risk 5.5% vs 1.9% and high risk 45% vs 22%). Kaplan-Meier analysis showed no difference in the risk of late recurrence among the UISS risk categories. CONCLUSIONS: The UISS model should be applied to tailor the early followup protocol after nephrectomy. Patients with low risk histology deserve less stringent followup regardless of the UISS risk category. Our results do not support a risk stratification model to design a surveillance protocol after 5 years postoperatively.
Authors: Luca Cindolo; Jean-Jacques Patard; Paolo Chiodini; Luigi Schips; Vincenzo Ficarra; Jacques Tostain; Alexandre de La Taille; Vincenzo Altieri; Bernard Lobel; Richard E Zigeuner; Walter Artibani; François Guillé; Claude C Abbou; Luigi Salzano; Ciro Gallo Journal: Cancer Date: 2005-10-01 Impact factor: 6.860
Authors: John S Lam; Oleg Shvarts; John T Leppert; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun Journal: J Urol Date: 2005-08 Impact factor: 7.450
Authors: Jean-Jacques Patard; Emmanuelle Leray; Nathalie Rioux-Leclercq; Luca Cindolo; Vincenzo Ficarra; Amnon Zisman; Alexandre De La Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; François Guillé; Dominique K Chopin; Peter F A Mulders; Christopher G Wood; David A Swanson; Robert A Figlin; Arie S Belldegrun; Allan J Pantuck Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Amnon Zisman; Allan J Pantuck; Jeffery Wieder; Debby H Chao; Fredrick Dorey; Jonathan W Said; Jean B deKernion; Robert A Figlin; Arie S Belldegrun Journal: J Clin Oncol Date: 2002-12-01 Impact factor: 44.544
Authors: Manlio A Goetzl; Manisha Desai; Mahesh Mansukhani; Erik T Goluboff; Aaron E Katz; Ihor S Sawczuk; Mitchell C Benson; Carl A Olsson; James M McKiernan Journal: Urology Date: 2004-01 Impact factor: 2.649
Authors: Chenghao Zhanghuang; Jinkui Wang; Zhigang Yao; Li Li; Yucheng Xie; Haoyu Tang; Kun Zhang; Chengchuang Wu; Zhen Yang; Bing Yan Journal: Front Public Health Date: 2022-04-04
Authors: Robert J Ellis; Sharon J Del Vecchio; Kevin M J Gallagher; Danielle N Aliano; Neil Barber; Damien M Bolton; Etienne T S Chew; Jeff S Coombes; Michael D Coory; Ian D Davis; James F Donaldson; Ross S Francis; Graham G Giles; Glenda C Gobe; Carmel M Hawley; David W Johnson; Alexander Laird; Steve Leung; Manar Malki; David J T Marco; Alan S McNeill; Rachel E Neale; Keng L Ng; Simon Phipps; Grant D Stewart; Victoria M White; Simon T Wood; Susan J Jordan Journal: J Am Soc Nephrol Date: 2020-04-01 Impact factor: 10.121